HOT NEWS
Aug 25,2025
Novelwise Pharmaceuticals Announces Collaboration with U.S. Patient Advocacy Group A Cure In Sight (ACIS) to Advance Ocular Melanoma Research
Novelwise Pharmaceuticals is honored to announce its collaboration with the U.S. patient advocacy organization A Cure In Sight (ACIS) in August 2025.
Jul 30,2025
Novelwise Pharmaceuticals Announces FDA “May Proceed” Clearance for Phase Ib/II Trial of NBM-BMX in Metastatic Uveal Melanoma
Taipei, July 30, 2025 —— Novelwise Pharmaceuticals today announced that its investigational cancer therapy NBM-BMX has been deemed may proceed by the United States Food and Drug Administration (US FDA).
About Us
Novelwise Pharmaceutical Corporation was formerly the New Drug Research and Development Department of NatureWise Biotech Medicals Corporation. We have over 20 years of experience in new drug development, including basic research, clinical translation, and strategic planning. As our new drug development projects reached significant milestones, the RD Department was established as a separate entity in 2023 to expedite its progress.
PRODUCTS
Metastatic Uveal Melanoma
NBM-BMX: Metastatic Uveal Melanoma (Phase 1b/2)
Glioblastoma
NBM-BMX: Glioblastoma (TW, Phase 1b/Expansion → Phase 2)
Advanced solid tumors
NBM-BMX: Advanced Solid Tumors (Phase 1, Dose Escalation) — Completed
Investigator-Initiated Trial
Hepatocellular Carcinoma：Investigator-Initiated TrialMesothelioma：Investigator-Initiated Trial